Harbin Gloria Pharmaceuticals (002437) — Free Cash Flow Generation Index
Harbin Gloria Pharmaceuticals (002437) has a Free Cash Flow Generation Index of 0.98x as of September 2025. Free cash flow of CN¥178.63 Million represents 1% of operating cash flow (CN¥182.89 Million). Read Harbin Gloria Pharmaceuticals (002437) total liabilities for a breakdown of total debt and financial obligations.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Harbin Gloria Pharmaceuticals Free Cash Flow Generation Index (2007–2025)
Historical FCF Generation Index trend for Harbin Gloria Pharmaceuticals across 19 annual periods. Explore capital reinvestment ratio of Harbin Gloria Pharmaceuticals to see what proportion of operating cash flow is directed to capital expenditures.
Annual Free Cash Flow Generation for Harbin Gloria Pharmaceuticals (2007–2025)
Year-by-year Free Cash Flow Generation Index for Harbin Gloria Pharmaceuticals. For the full company profile including market capitalisation, see Harbin Gloria Pharmaceuticals (002437) total market value.
| Year | FCG Index | Free Cash Flow (CNY) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.91x | CN¥249.54 Million | CN¥273.36 Million | CN¥23.81 Million | ▲ +7.8% |
| 2024 | 0.85x | CN¥348.04 Million | CN¥410.94 Million | CN¥62.90 Million | ▼ -5.0% |
| 2023 | 0.89x | CN¥244.55 Million | CN¥274.18 Million | CN¥29.62 Million | ▲ +2.1% |
| 2022 | 0.87x | CN¥228.60 Million | CN¥261.62 Million | CN¥33.01 Million | ▼ 0.0% |
| 2021 | 0.87x | CN¥239.67 Million | CN¥274.18 Million | CN¥34.51 Million | ▲ +136.1% |
| 2020 | -2.42x | CN¥-30.90 Million | CN¥12.76 Million | CN¥43.66 Million | ▼ -362.9% |
| 2019 | 0.92x | CN¥561.94 Million | CN¥610.37 Million | CN¥48.43 Million | ▲ +1.1% |
| 2018 | 0.91x | CN¥1.06 Billion | CN¥1.16 Billion | CN¥104.34 Million | ▲ +29.8% |
| 2017 | 0.70x | CN¥457.16 Million | CN¥651.80 Million | CN¥194.63 Million | ▼ -14.7% |
| 2016 | 0.82x | CN¥855.14 Million | CN¥1.04 Billion | CN¥185.34 Million | ▲ +37.7% |
| 2015 | 0.60x | CN¥418.95 Million | CN¥702.05 Million | CN¥283.10 Million | ▼ -26.6% |
| 2014 | 0.81x | CN¥548.14 Million | CN¥674.04 Million | CN¥125.89 Million | ▲ +27.2% |
| 2013 | 0.64x | CN¥289.67 Million | CN¥453.02 Million | CN¥163.35 Million | ▲ +114.0% |
| 2012 | 0.30x | CN¥61.52 Million | CN¥205.89 Million | CN¥144.37 Million | ▲ +200.3% |
| 2011 | -0.30x | CN¥-38.30 Million | CN¥128.61 Million | CN¥166.90 Million | ▲ +73.9% |
| 2010 | -1.14x | CN¥-128.29 Million | CN¥112.59 Million | CN¥240.88 Million | ▼ -278.0% |
| 2009 | 0.64x | CN¥109.34 Million | CN¥170.82 Million | CN¥61.47 Million | ▲ +87.5% |
| 2008 | 0.34x | CN¥19.73 Million | CN¥57.81 Million | CN¥38.08 Million | ▼ -54.4% |
| 2007 | 0.75x | CN¥39.09 Million | CN¥52.26 Million | CN¥13.17 Million | — |